MDXXF (Pharmala Biotech Holdings) Inventory Turnover: 0.06 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXXF Pharmala Biotech Holdings Inc MDXXF
33 GF Score
Price $0.11
GF Value $0.15
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Pharmala Biotech Holdings Inventory Turnover?

Pharmala Biotech Holdings MDXXF 33 Inventory Turnover is 0.06 as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.15 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Pharmala Biotech Holdings's Cost of Goods Sold for the three months ended in Feb. 2026 was $0.02 Mil. Pharmala Biotech Holdings's Average Total Inventories for the quarter that ended in Feb. 2026 was $0.27 Mil. Pharmala Biotech Holdings's Inventory Turnover for the quarter that ended in Feb. 2026 was 0.06.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Pharmala Biotech Holdings's Days Inventory for the three months ended in Feb. 2026 was 1,446.58.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Pharmala Biotech Holdings's Inventory-to-Revenue for the quarter that ended in Feb. 2026 was 1.31.

Pharmala Biotech Holdings  (OTCPK:MDXXF) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pharmala Biotech Holdings's Days Inventory for the three months ended in Feb. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Feb. 2026 )/Cost of Goods Sold (Q: Feb. 2026 )*Days in Period
=0.2695/0.017*365 / 4
=1,446.58

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pharmala Biotech Holdings's Inventory to Revenue for the quarter that ended in Feb. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Feb. 2026 ) / Revenue (Q: Feb. 2026 )
=0.2695 / 0.206
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Pharmala Biotech Holdings Inventory Turnover Related Terms

Pharmala Biotech Holdings Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Inventory Turnover Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Inventory Turnover
0.00 0.01 0.64 0.62 0.15

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.09 0.10 0.06
MDXXF
33GF Score
Pharmala Biotech Holdings Inc MDXXF
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings Inventory Turnover Calculation

Pharmala Biotech Holdings's Inventory Turnover for the fiscal year that ended in Aug. 2025 is calculated as

Inventory Turnover (A: Aug. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Aug. 2025 ) / ((Total Inventories (A: Aug. 2024 ) + Total Inventories (A: Aug. 2025 )) / count )
=0.039 / ((0.259 + 0.268) / 2 )
=0.039 / 0.2635
=0.15

Pharmala Biotech Holdings's Inventory Turnover for the quarter that ended in Feb. 2026 is calculated as

Inventory Turnover (Q: Feb. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Feb. 2026 ) / ((Total Inventories (Q: Nov. 2025 ) + Total Inventories (Q: Feb. 2026 )) / count )
=0.017 / ((0.255 + 0.284) / 2 )
=0.017 / 0.2695
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.06 mean?
Pharmala Biotech Holdings (MDXXF) has a Inventory Turnover of 0.06 as of Feb. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' Inventory Turnover too high?
Pharmala Biotech Holdings' current Inventory Turnover is 0.06. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Inventory Turnover compare to VRTX and REGN?
Pharmala Biotech Holdings' Inventory Turnover of 0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current Inventory Turnover is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 29.5% below its estimated fair value. The current Inventory Turnover is 0.06. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Inventory Turnover is 0.06 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 29.5% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Significantly Undervalued.

Key valuation signals for MDXXF:

  • Inventory Turnover: 0.06
  • GF Value™: $0.15 vs. price of $0.11 (29.5% below fair value)
  • GF Score™: 33/100 with 2 warning signs

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score

Get the complete analysis for MDXXF

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value